AUPH trades 2.4% above Wall Street's consensus target of $16.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes AUPH achieves its forward estimates and maintains a stable P/E multiple of 17.4x. This scenario reflects the blended consensus of 15 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Aurinia Pharmaceuticals Inc. (AUPH) has a Wall Street consensus price target of $16.00, based on estimates from 15 covering analysts. With the stock currently trading at $16.40, this represents a potential downside of -2.4%. The company has a market capitalization of $2.11B.
Analyst price targets range from a low of $16.00 to a high of $16.00, representing a 0% spread in expectations. The median target of $16.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 11 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, AUPH trades at a trailing P/E of 7.9x and forward P/E of 17.4x. Analysts expect EPS to grow -59.9% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $5.67, with bear and bull scenarios of $3.57 and $7.46 respectively. Model confidence stands at 60/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 LGNDLigand Pharmaceuticals Incorporated | $6.0B | $298.41 | $338.50 | +13.4% | Buy | 32.0x | 18 |
 ANIPANI Pharmaceuticals, Inc. | $1.7B | $74.43 | $104.33 | +40.2% | Buy | 8.0x | 10 |
 PRAXPraxis Precision Medicines, Inc. | $7.9B | $282.12 | $603.83 | +114.0% | Buy | — | 18 |
 CORTCorcept Therapeutics Incorporated | $12.1B | $112.94 | $125.33 | +11.0% | Buy | 54.8x | 26 |
 GSKGSK plc | $99.6B | $49.71 | $60.00 | +20.7% | Hold | 13.8x | 29 |
 BIIBBiogen Inc. | $33.6B | $227.53 | $245.88 | +8.1% | Buy | 18.3x | 49 |
 ALNYAlnylam Pharmaceuticals, Inc. | $32.9B | $246.51 | $347.33 | +40.9% | Buy | 36.9x | 52 |
 VKTXViking Therapeutics, Inc. | $4.9B | $41.65 | $91.75 | +120.3% | Buy | — | 24 |
 IQVIQVIA Holdings Inc. | $44.1B | $267.86 | $246.13 | -8.1% | Buy | 20.7x | 45 |
 CRLCharles River Laboratories International, Inc. | $13.4B | $277.33 | $282.36 | +1.8% | Buy | 24.5x | 37 |
Quick answers to the most common questions about buying AUPH stock.
Wall Street's consensus price target for AUPH is $16, -2.4% from its current price of $16.4. The below-market target from 15 analysts suggests limited near-term appreciation.
AUPH has a consensus rating of "Buy" based on 15 Wall Street analysts. The rating breakdown is predominantly bullish, with 11 Buy/Strong Buy ratings. The consensus 12-month price target of $16 implies -2.4% downside from current levels.
With a forward P/E of 17.3729x, AUPH trades at a relatively low valuation. The consensus target of $16 implies -2.4% move, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $16 for AUPH, while the most conservative target is $16. The consensus of $16 represents the median expectation. Our quantitative valuation model projects a bull case target of $7 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
AUPH is well covered by analysts, with 15 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 11 have Buy ratings, 4 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month AUPH stock forecast based on 15 Wall Street analysts shows a consensus price target of $16, with estimates ranging from $16 (bear case) to $16 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $6, with bear/bull scenarios of $4/$7.
Our quantitative valuation model calculates AUPH's fair value at $6 (base case), with a bear case of $4 and bull case of $7. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 60/100.
AUPH trades at a forward P/E ratio of 17.4x based on next-twelve-months earnings estimates compared to a trailing P/E of 7.9x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on AUPH, with 0 Sell ratings and a price target of $16 (-2.4% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
AUPH analyst price targets range from $16 to $16, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $16 consensus represents the middle ground. Our model's $4-$7 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.